✨ Free AI Report
Passage Bio, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Passage Bio, Inc.
Company Research

Passage Bio, Inc.: Business Overview, Financials & Competitive Analysis

Passage Bio, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Clinical validation of PBFT02 with extended cash runway and FDA alignment positions Passage Bio for pivotal trial progression in high-value neurodegenerative disease market. Passage Bio reported significant positive updates on PBFT02 clinical trial with promising interim results including robust progranulin elevation and improvement in disease progression biomarkers. Cash runway.

What is Passage Bio, Inc.'s industry? Passage Bio, Inc. (passagebio.com) operates in Genetic Medicines / Gene Therapy - CNS Neurodegenerative Diseases. AskCyborg classifies Passage Bio, Inc. under Genetic Medicines / Gene Therapy - CNS Neurodegenerative Diseases in its company registry.

Passage Bio is a clinical-stage genetic medicines company focused on developing one-time therapies targeting the underlying pathology of neurodegenerative diseases. The lead product candidate, PBFT02, seeks to treat f...

7/ 10Strong

Cyborg Score thesis

Clinical validation of PBFT02 with extended cash runway and FDA alignment positions Passage Bio for pivotal trial progression in...

Read the full analyst-debate transcript →
Industry Genetic Medicines / Gene Therapy - CNS Neurodegenerative Diseases
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest Passage Bio, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Passage Bio, Inc.

AskCyborg analysts argue the bull and bear cases for Passage Bio, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Passage Bio, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Passage Bio, Inc. Overview

Pro stress-test →

Passage Bio is a clinical-stage genetic medicines company focused on developing one-time therapies targeting the underlying pathology of neurodegenerative diseases. The lead product candidate, PBFT02, seeks to treat frontotemporal dementia by elevating progranulin levels to restore lysosomal function and slow disease progression.

Strategic Profile

Pro stress-test →

Passage Bio delivered promising data in 2024 showing durable progranulin expression and completed development and scale-up of a high-productivity, suspension-based manufacturing process. The company benefits from strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program and partnership agreements with Catalent Maryland.

Competitive Landscape

Pro stress-test →

Passage Bio competes in AAV gene therapy space with competitors including Sarepta Therapeutics focused on rare neurological diseases and CRISPR/Intellia Therapeutics developing gene therapies for severe rare neurological conditions. Passage Bio differentiates through focused CNS neurodegenerative disease portfolio and proprietary suspension-based manufacturing approach enabling potential dose flexibility.

Industry Context

Passage Bio, Inc. operates in Genetic Medicines / Gene Therapy - CNS Neurodegenerative Diseases.

Key facts

Founded: 2017 · Headquarters: Philadelphia, US · Employees: 65 · Revenue: $35M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Passage Bio, Inc..

  • Dose 2 PBFT02 is 50% lower than Dose 1, with expectations to report 12-month data from Dose 1 and interim safety data from Dose 2 in H2 2025
  • Actively enrolling patients in Cohorts 3-4 of upliFT-D study targeting FTD-GRN and FTD-C9orf72 variants with protocol amendments for broader early-stage enrollment
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025Reported positive interim data from upliFT-D study Cohort 2 with robust progranulin elevation and biomarker improvement
  • November 2025Announced FDA alignment on analytical comparability for suspension-based PBFT02 manufacturing process
  • +2 moreTrack every material event for Passage Bio, Inc. as it happens. Explore monitoring →
Get alerted when Passage Bio, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Gene Therapies for Rare Neurological DiseasesFocused on genetic medicines for rare neurological conditions→AAV Gene Therapy PlatformDevelops gene therapies for severe rare conditions→AAV Gene Therapy PlatformDevelops gene therapies for severe rare neurological conditions→

Compare Passage Bio, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Passage Bio, Inc. operates in Genetic Medicines / Gene Therapy - CNS Neurodegenerative Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Genetic Medicines / Gene Therapy - CNS Neurodegenerative Diseases research →
NEW · MCP server

Ask your AI assistant about Passage Bio, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Passage Bio, Inc. and its top competitor on Cyborg Score”
“What did Passage Bio, Inc. do this quarter?”
“Is Passage Bio, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Passage Bio, Inc. do?+
Passage Bio is a clinical-stage genetic medicines company focused on developing one-time therapies targeting the underlying pathology of neurodegenerative diseases. The lead product candidate, PBFT02, seeks to treat f...
What is Passage Bio, Inc.'s Cyborg Score?+
Passage Bio, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Passage Bio, Inc.'s main competitors?+
Named competitors include Gene Therapies for Rare Neurological Diseases, AAV Gene Therapy Platform, AAV Gene Therapy Platform. The full competitive landscape is in the AskCyborg report.
How can I get the full Passage Bio, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Passage Bio, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Passage Bio, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Genetic Medicines research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Passage Bio, Inc.